Wellington Management Group LLP Has $219,000 Holdings in Halozyme Therapeutics, Inc. $HALO

Wellington Management Group LLP cut its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 72.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,794 shares of the biopharmaceutical company’s stock after selling 7,494 shares during the quarter. Wellington Management Group LLP’s holdings in Halozyme Therapeutics were worth $219,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Empowered Funds LLC bought a new position in Halozyme Therapeutics during the 1st quarter worth $755,000. Acadian Asset Management LLC bought a new stake in shares of Halozyme Therapeutics during the 1st quarter valued at $195,000. Hsbc Holdings PLC lifted its position in shares of Halozyme Therapeutics by 117.1% during the 2nd quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock valued at $522,000 after acquiring an additional 5,448 shares during the period. EverSource Wealth Advisors LLC grew its holdings in shares of Halozyme Therapeutics by 6.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 174 shares in the last quarter. Finally, Baird Financial Group Inc. grew its holdings in shares of Halozyme Therapeutics by 6.2% during the 2nd quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock worth $577,000 after purchasing an additional 650 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $107.20 on Friday. Halozyme Therapeutics, Inc. has a one year low of $61.22 and a one year high of $111.15. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. The company has a market cap of $12.17 billion, a price-to-earnings ratio of 32.00, a PEG ratio of 0.41 and a beta of 0.88. The firm has a 50 day simple moving average of $93.73 and a 200 day simple moving average of $76.97.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. The firm had revenue of $481.00 million for the quarter, compared to analysts’ expectations of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The company’s revenue was up 47.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Research analysts predict that Halozyme Therapeutics, Inc. will post 8.25 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the sale, the director directly owned 40,418 shares of the company’s stock, valued at approximately $4,154,970.40. This trade represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $107.24, for a total value of $2,144,800.00. Following the sale, the chief executive officer owned 767,780 shares in the company, valued at approximately $82,336,727.20. This trade represents a 2.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 72,478 shares of company stock worth $7,370,004 in the last 90 days. Insiders own 2.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on HALO shares. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. HC Wainwright reiterated a “buy” rating and set a $115.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, September 2nd. TD Cowen increased their price objective on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Wells Fargo & Company raised their target price on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. Finally, Leerink Partners upgraded shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $83.00 to $110.00 in a research report on Friday, August 7th. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $91.20.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company’s primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.